What We Offer

Built to Accelerate Your Research

Our services are designed to accelerate your cancer research and drug development.

1
Preclinical Pharmacology Studies (PD/PK, Acute Toxicology)

Vivarium & In vivo Pharmacology Program

Two dedicated animal rooms with IVC racks. Subcutaneous and orthotopic human tumor mouse models including PDOX, metastasis, recurrence, PK/PD, and acute toxicology.

2
Dual Humanized Tumor and Immune System Xenograft Tumor Models Study

Primarily applied in the study of tumor-immune interactions and the development and evaluation of immunotherapies, offering higher clinical relevance for preclinical testing.

3
Advanced Imaging & Tumor Visualization Models Study

Enable real-time, non-invasive monitoring of tumor growth and treatment response in orthotopic tumor models, enhancing the efficiency and accuracy of in vivo drug efficacy assessments.

4
Metastatic Cancer Mouse Models Study

Designed to explore the mechanisms of cancer metastasis and provide foundational models for the development and evaluation of anti-metastatic therapies.

5
Personalized Precision Cancer Treatment Studies

Support the development of personalized cancer treatment strategies based on individual tumor characteristics, and facilitate research on tumor heterogeneity and drug resistance.

6
EchoMRI-Based Metabolic Disease Research

The EchoMRI system offers rapid, repeatable, and anesthesia-free measurements of fat mass, lean mass, and body water in small animals. As a globally recognized tool in metabolic phenotyping, it plays a crucial role in evaluating the progression of metabolic disorders and the efficacy of therapeutic interventions.

7
Histopathology Study

At VivoxBio, our Histopathology Division provides comprehensive, expert-driven tissue processing, analysis, and interpretation services to support and accelerate your drug development programs. From necropsy to digital pathology, we offer end-to-end solutions tailored to your research needs. Learn More

Our Edge

Why VivoxBio

  • Clinical relevance of PDOX/PDX tumor models
  • Proprietary CQD tracers (OncoReveal™) for real-time tracking
  • OncoExo™ exosome platform for personalized studies
  • High-throughput imaging workflow and rapid turnaround
  • AAALAC-ready animal facility + strict confidentiality/IP protection
Rapid In Vivo Screening
  • 3–5 mice/group; 2–3 dose levels
  • Imaging endpoints for candidate triage
  • Typical turnaround: 3–4 weeks

Testimonials

What Our Clients Say

Interested in our services?

Contact us to discuss how we can support your research needs.